Objectives To study women who initiated aspirin in the first trimester for high risk of pre-eclampsia, and compare blood-pressure 9.4 (95% CI, P < 0.001) and that for early-onset disease was 34.6 (95% CI,; P = 0.004). 
INTRODUCTION
The initiation of aspirin prophylaxis in pregnant women before 16 weeks' gestation has been associated with a significant dose-dependent reduction in the relative risk of developing pre-eclampsia or delivering a small-for-gestational-age (SGA) neonate 1 . However, even in patients initiating prophylaxis by 16 weeks, the residual prevalence of pre-eclampsia may be as high as 9.3%, indicating that not all predisposing risks are mitigated. We have shown previously that, in women receiving prophylactic aspirin, higher blood pressure measured on a single occasion between 11 and 14weeks is associated with an increased risk for pre-eclampsia 2, 3 . To clarify if this association is related to a single observation in the first trimester or sustained blood-pressure trends across all trimesters requires that serial blood-pressure observations be made through pregnancy. Determining these relationships is important not only for understanding the contributors to developing pre-eclampsia but also for identifying potential approaches to its prevention. Accordingly, it was our aim in this study to test the hypothesis that elevated blood pressure throughout pregnancy is related to the development of pre-eclampsia in women who start aspirin prophylaxis by 16 weeks' gestation.
PATIENTS AND METHODS
Women at 9-14 weeks' gestation were recruited into a prospective observational study 4 . After obtaining written informed consent at the enrollment visit, women provided demographic and medical information on a standardized questionnaire, followed by an ultrasound examination, maternal physical examination and determination of maternal serum analytes. Following enrollment, women continued prenatal care with their primary obstetric providers. At delivery, pregnancy outcomes, including the development of pre-eclampsia and neonatal birth weight, were recorded, and source documentation about the birth circumstances was provided to the principal investigator. Pre-eclampsia was defined as maternal systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg on two separate occasions at least 6 h apart, accompanied by proteinuria and/or thrombocytopenia, pulmonary edema, renal insufficiency, impaired liver function or persistent neurologic symptoms, after 20 weeks' gestation. Pre-eclampsia requiring delivery before 34 weeks was defined as early onset. Chronic hypertension with superimposed pre-eclampsia was defined as worsening blood pressure and increasing proteinuria after 20 weeks' gestation, with or without features of severe disease 5 . SGA was defined as birth weight below the 10 th percentile for gestational age. Clinical surveillance and management of these conditions were at the discretion of the attending physician.
This secondary analysis was confined to study participants who initiated aspirin by 16 weeks' gestation and received all prenatal care at the primary study site, allowing for multiple observations across pregnancy. Aspirin prophylaxis (81 mg/day) was recommended at the time of first-trimester screening for women at high risk of developing pre-eclampsia based on history 6 , or if there was associated bilateral uterine artery notching 7 . Adherence to aspirin prophylaxis was verified at each subsequent prenatal visit after enrollment and recorded in the patient's chart. Only patients in whom adherence to aspirin prophylaxis could be verified by such source documentation were included. Blood pressure was measured by trained medical personnel using an automated sphygmomanometer (Spot Vital Signs ® 420; Welch Allyn ® , New York, USA) validated for use in pregnancy and calibrated to an accuracy within ± 3 mmHg according to the American National Institute of Standards and Technology and an appropriately sized cuff, with the patient in a seated position after 5 min rest. The same equipment and technique used to measure blood pressure was utilized at enrollment and at follow-up examinations. As a minimum, every patient had blood-pressure measurement every 4 weeks until 28 weeks' gestation, every 2 weeks between 28 and 36 weeks and weekly thereafter. The frequency of blood-pressure monitoring was increased if clinically indicated, at the discretion of the managing obstetrician. Elevated blood pressure was confirmed by a second reading and classified according to the criteria of the Joint National Committee on Hypertension-7 (JNC-7) 8 . Prehypertension was defined as systolic blood pressure of 120-139 mmHg or diastolic blood pressure of 80-89 mmHg, and hypertension as systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg.
First-trimester characteristics at enrollment, average blood pressure in each trimester and blood-pressure trends throughout pregnancy were compared between women who developed pre-eclampsia and those who did not. Maternal history, demographics, systolic blood pressure, diastolic blood pressure, mean arterial pressure, body mass index (BMI), uterine artery pulsatility index Z-score, pregnancy-associated plasma protein-A multiples of the median and human chorionic gonadotropin multiples of the median were compared using chi-square, Fisher's exact or parametric tests as appropriate. Blood-pressure trends were analyzed using a general linear model approach accounting for repeat measures. Determination of statistically significant differences between trends was by comparison of the slope and intercept of the regression lines fitted for each group. Normal distribution of data was evaluated using the Shapiro-Wilk test. Post-hoc analyses included logistic regression to determine important contributors to the development of pre-eclampsia, and receiver-operating characteristics (ROC) curves to determine ideal predictive cut-offs for continuous variables. Statistical analysis was carried out using SPSS 20.0 software (IBM Corp., Armonk, NY, USA), and P < 0.05 was considered to indicate statistical significance.
RESULTS
Seven hundred and ninety-eight women received ongoing prenatal care at the primary study center and were potentially eligible for this study. Of these, 237 (29.7%) commenced low-dose aspirin (81 mg/day) by 16 weeks' gestation and continued taking it until delivery or 34 weeks. In this study cohort, 2881 blood-pressure readings were obtained between 4 and 41 weeks' gestation (747 in the first trimester, 1008 in the second and 1126 in the third). Subsequently, 29 (12.2%) women developed pre-eclampsia, seven of whom (3.0% of the whole study population) required delivery before 34 weeks for early-onset pre-eclampsia. Enrollment characteristics are presented in Table 1 .
At enrollment, women who developed pre-eclampsia, especially those who developed early-onset pre-eclampsia, had higher blood pressure and BMI, while their Data are given as median (range), mean ± SD or n (%). β-hCG, betahuman chorionic gonadotropin; BMI, body mass index; BP, blood pressure; MoM, multiples of the median; PAPP-A, pregnancyassociated plasma protein-A; PI, pulsatility index; UtA, uterine artery.
first-trimester mean uterine artery pulsatility index Z-scores were similar ( Table 2 ). The number of blood-pressure measurements was similar between groups in the first and second trimesters. However, in the third trimester, women with pre-eclampsia had fewer blood-pressure measurements, as they were delivered earlier ( Table 2) . Women who developed pre-eclampsia had the highest average blood-pressure values and weight in all three trimesters. Pre-eclampsia was associated with earlier delivery and birth of a SGA infant (Table 2) . When longitudinal trends of blood pressure for individual women were evaluated, those who developed pre-eclampsia had a significant and sustained difference in blood-pressure distribution from the beginning of pregnancy until delivery. The trend for mean arterial blood pressure in women with subsequent pre-eclampsia was (0.13 × gestational age (weeks)) + 93.63; r 2 = 0.96571, compared with (0.11 × gestational age (weeks)) + 82.61; r 2 = 0.8963 in those without (P < 0.005) (Figure 1) .
Logistic regression analysis identified average first-trimester diastolic and second-trimester systolic blood pressure as independent risk factors for all cases of pre-eclampsia (β = 1.087 and 1.050, respectively; r 2 = 0.24; P < 0.0001). ROC curve analysis identified the best predictive cut-offs as being first-trimester average diastolic blood pressure > 74 mmHg (area under the ROC curve (AUC) 0.78 (95% CI, 0.70-0.85); P < 0.0001; sensitivity 75%, specificity 71%), and second-trimester average systolic blood pressure > 125 mmHg (AUC 0.75 (95% CI, 0.65-0.85); P < 0.0001; sensitivity 59%, specificity 87%). Early-onset pre-eclampsia was related primarily to average first-trimester diastolic blood pressure (β = 1.196; r 2 = 0.31; P < 0.0001) with ROC analysis identifying a value of >77 mmHg as the best predictive cut-off (AUC 0.89 (95% CI, 0.78-1.0); P < 0.0001; sensitivity 86%, specificity 80%).
An average first-trimester diastolic blood pressure > 74 mmHg was associated with an odds ratio (OR) of 6.5 (95% CI, 2.8-15.1) (P < 0.001) for pre-eclampsia overall and 14.6 (95% CI, 1.72-123.5) (P = 0.004) for early-onset pre-eclampsia. Only one of 164 (0.6%) women with a first-trimester diastolic blood pressure below this threshold developed early-onset pre-eclampsia and eight (4.9%) developed pre-eclampsia ≥ 34 weeks' gestation. Of the 190 women with average second-trimester systolic blood pressure < 125 mmHg, one (0.5%) developed early-onset and 11 (5.8%) developed late-onset pre-eclampsia. When an average first-trimester diastolic blood pressure over 74 mmHg was also associated with second-trimester systolic blood pressure over 125 mmHg, the OR for pre-eclampsia overall was 9.4 (95% CI, 4.1-22.4) (P < 0.001) and for early-onset disease it was 34.6 (95% CI, 4.1-296.4) (P = 0.004). Conversely, for women with average firstand second-trimester blood-pressure values below these Data are given as mean (range) or n (%). BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; IUFD, intrauterine fetal death; PI, pulsatility index; SBP, systolic blood pressure; UtA, uterine artery.
thresholds, the odds of developing pre-eclampsia overall and before 34 weeks were reduced significantly (OR 0.17 (95% CI, 0.01-0.32) and 0.03 (95% CI, 0.0-0.27), respectively) (P < 0.001 for both).
DISCUSSION
Aspirin prophylaxis has to be initiated by 16 weeks' gestation to reduce significantly the risk of subsequent pre-eclampsia or delivery of a SGA infant 1, 9 . It has been shown previously that, even in women receiving first-trimester aspirin, maternal characteristics, such as higher blood pressure or BMI, on a single occasion in the first trimester lead to failure of aspirin prophylaxis 3, 10 . In this longitudinal study of women initiating aspirin in the first trimester, we were able to show that the development of pre-eclampsia is related to higher blood-pressure values from the beginning of pregnancy.
The impact of gestational blood-pressure trends on the development of maternal hypertensive disorders of pregnancy has been demonstrated in several large studies. In normal pregnancy, mean first-trimester systolic and diastolic blood pressures rise only minimally, from 112 mmHg and 65 mmHg, respectively, to 116 mmHg and 70 mmHg, respectively, by the third trimester 11 . Even in normotensive women, first-trimester characteristics, such as blood pressure at enrollment, pre-pregnancy BMI and smoking, significantly affect second-and third-trimester blood-pressure values. Compared with normotensive women, those with a hypertensive disorder have significantly higher blood pressure from the first trimester onward, with a high chance of maintaining their high blood-pressure tertile throughout pregnancy 12, 13 .
First-trimester blood pressure, BMI, smoking and ethnicity further modify blood-pressure trends [11] [12] [13] [14] . In contrast to gestational or chronic hypertension, pre-eclampsia follows a steeper rise in early second-trimester diastolic blood pressure prior to rising systolic blood pressure 13, 14 . This sequential increase is potentially attributable to diastolic blood pressure being a primary modulator of vascular adaptation, with increasing systolic blood pressure representing the clinical appearance of pre-eclampsia. Our findings are consistent with those of larger studies. In that by Gaillard et al., pre-eclamptic women had mean systolic blood pressures of 120 mmHg, 121 mmHg and 125 mmHg, and diastolic blood pressures of 73 mmHg, 73 mmHg and 77 mmHg in the first, second and third trimesters, respectively 13 . Accordingly, there is a clear separation in blood-pressure trends in women destined to develop pre-eclampsia, which is maintained from the onset of pregnancy. Importantly, average blood pressure in these women is well below current treatment thresholds 15 . Almost all these women also had elevated first-trimester uterine artery blood flow resistance, suggesting an inter-relationship between early gestational blood pressure, placentation, subsequent blood-pressure trends and subsequent development of pre-eclampsia.
Aspirin facilitates the placental vascular adaptation that is required for successful pregnancy outcome, and longitudinal observations demonstrate that its intake is associated with accelerated decrease in uterine artery blood flow resistance 1, 16, 17 . Such facilitated placental vascular development may be responsible for the benefits of aspirin demonstrated recently in observational and randomized trials in which initiation of 150 mg of aspirin daily led to a ten-fold decrease in early-onset disease 9, 18 . In our population, the residual rate of pre-eclampsia was much higher, and only women with average blood pressure below 125/75 mmHg achieved a pre-eclampsia rate resembling that in low-risk populations 9, 15 . This suggests that there is an independent contribution of a woman's gestational blood-pressure trend to developing pre-eclampsia, which is not mitigated by low-dose aspirin. The risk reduction conveyed by aspirin occurs in a dose-dependent fashion, and it remains to be determined if the emergence of pre-eclampsia can be mitigated by a higher aspirin dose 1 . However, as pre-eclampsia still occurs with higher-dose aspirin treatment, albeit at a much lower rate, we hypothesize that maternal gestational blood-pressure trend is an independent risk contributor.
Women who subsequently developed pre-eclampsia had two synergistic risk factors: abnormal uterine artery Doppler at enrollment and higher blood pressure throughout pregnancy. Large population studies have demonstrated that synergy decreases the threshold at which risk factors can produce disease. For example, blood-pressure treatment thresholds are lower in patients with comorbidities such as diabetes or obesity in order to prevent disease 19, 20 . Similarly, early abnormal placentation appears to lower the threshold of gestational blood-pressure trends that are associated with pre-eclampsia. It is at present unclear if this is only of prognostic 21, 22 , or also of therapeutic, value 23 . A small randomized trial and a recent observational study demonstrated significantly lower pre-eclampsia and SGA rates in women with prehypertension at first-trimester enrollment who maintained lower blood pressure throughout pregnancy 24, 25 . The idea that women with significant first-trimester risk of pre-eclampsia may benefit from normalization of blood pressure to values associated with completely normal pregnancy outcome merits evaluation in a randomized trial 11, 13, 26 .
Limitations of our study include the low aspirin dose, small sample size of women with adverse outcome and a predominantly urban African-American population, which may make our results less generalizable and may also explain the significantly higher rate of pre-eclampsia than in the recently reported ASPRE trial 18 . As the subanalysis of ASPRE confirms, maternal blood-pressure profiles may also have impacted significantly on the efficacy of aspirin 27 . Our data were obtained in two settings; study enrollment, regular prenatal care visits and enrollment markers were not analyzed serially and therefore limit the ability to analyze mechanistic explanations for our observations. Strengths of the study are the prospective design and the verification of aspirin intake and outcomes by source information and uniform ascertainment of blood pressure in both arms. While we were unable to determine the magnitude of the effect of blood pressure in the context of a wider population, our observations confirm that women who develop pre-eclampsia have significantly higher blood pressure from the onset of pregnancy. In the presence of early abnormal placentation, blood-pressure levels that lead to pre-eclampsia are only mildly elevated compared with those in women who remain normotensive. Since aspirin does not completely mitigate placenta-based disease, and since blood pressure may be abnormal from the onset of pregnancy, it raises the possibility that placentation is not the sole initiator of a woman's developing pre-eclampsia. It could therefore be hypothesized that early prehypertension causes abnormal placentation in susceptible women, and that the synergy of these two factors increases the risk for pre-eclampsia.
